Granulocyte transfusions in the G-CSF era. Where do we stand?
The efficacy of granulocytes transfusions (GTX) in either the prevention or treatment of neutropenic sepsis has been a controversial issue. Early studies employing steroid mobilised GTX showed variable, dose-dependent results and significant pulmonary toxicity was reported. With the introduction of the recombinant myeloid growth factor, granulocyte-colony stimulating factor (G-CSF), the quantity of granulocytes that could be harvested was substantially increased leading to renewed interest in the clinical application of GTX. The administration of G-CSF to normal donors leads to significantly higher pre-harvest neutrophil counts and consequently larger granulocyte harvests. Infusion of G-CSF stimulated GTX results in measurable increases in the recipients' neutrophil count and may reduce the duration and severity of neutropenia. However, the efficacy of these GTX in treating or preventing established neutropenic sepsis remains to be established in prospective controlled clinical trials.
Robinson
S P
SP
Bristol Royal Children's Hospital, Bristol, UK. stephen.robinson@ubht.swest.nhs.uk
Marks
D I
DI
D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006098:Granulocytes / Q000637:transplantation*; D006801:Humans; D007937:Leukapheresis / Q000379:methods; D017708:Leukocyte Transfusion / Q000009:adverse effects / Q000379:methods* / Q000639:trends*; D009503:Neutropenia / Q000150:complications / Q000628:therapy*; D018805:Sepsis / Q000517:prevention & control
D016179:Granulocyte Colony-Stimulating Factor